Aytu BioPharma analyst ratings
Aytu BioPharma analyst ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
04/28/2022 | 1688.62% | HC Wainwright & Co. | $24 → $11 | Maintains | Buy |
03/30/2021 | 1688.62% | Cantor Fitzgerald | → $11 | Initiates Coverage On | → Overweight |
05/29/2020 | 387.8% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
10/22/2018 | 1526.02% | Northland Capital Markets | → $10 | Initiates Coverage On | → Outperform |
Aytu BioPharma Questions & Answers
The latest price target for Aytu BioPharma (NASDAQ: AYTU) was reported by HC Wainwright & Co. on April 28, 2022. The analyst firm set a price target for $11.00 expecting AYTU to rise to within 12 months (a possible 1688.62% upside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Aytu BioPharma (NASDAQ: AYTU) was provided by HC Wainwright & Co., and Aytu BioPharma maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aytu BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aytu BioPharma was filed on April 28, 2022 so you should expect the next rating to be made available sometime around April 28, 2023.
While ratings are subjective and will change, the latest Aytu BioPharma (AYTU) rating was a maintained with a price target of $24.00 to $11.00. The current price Aytu BioPharma (AYTU) is trading at is $0.62, which is out of the analyst's predicted range.
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
04/28/2022 | 1688.62% | HC Wainwright & Co. | $24 → $11 | Maintains | Buy |
03/30/2021 | 1688.62% | Cantor Fitzgerald | → $11 | Initiates Coverage On | → Overweight |
05/29/2020 | 387.8% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
10/22/2018 | 1526.02% | Northland Capital Markets | → $10 | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
---|---|---|---|---|---|
04/28/2022 | 1688.62% | HC Wainwright公司 | $24 → $11 | 維護 | 買 |
03/30/2021 | 1688.62% | 康託·菲茨傑拉德 | → $11 | 開始承保 | →超重 |
05/29/2020 | 387.8% | HC Wainwright公司 | → $3 | 開始承保 | →購買 |
10/22/2018 | 1526.02% | 北國資本市場 | → $10 | 開始承保 | →跑贏大盤 |
Aytu BioPharma Questions & Answers
Aytu BioPharma問答
The latest price target for Aytu BioPharma (NASDAQ: AYTU) was reported by HC Wainwright & Co. on April 28, 2022. The analyst firm set a price target for $11.00 expecting AYTU to rise to within 12 months (a possible 1688.62% upside). 1 analyst firms have reported ratings in the last year.
愛圖生物製藥(納斯達克:AYTU)的最新目標價是由HC Wainwright&Co.於2022年4月28日報道的。這家分析公司將目標價定為11美元,預計AYTU將在12個月內上漲至(可能上漲1688.62%)。1家分析公司在過去一年公佈了評級。
The latest analyst rating for Aytu BioPharma (NASDAQ: AYTU) was provided by HC Wainwright & Co., and Aytu BioPharma maintained their buy rating.
納斯達克(Sequoia Capital:AYTU)的最新分析師評級由HC Wainwright&Co.提供,Aytu BioPharma維持買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aytu BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aytu BioPharma was filed on April 28, 2022 so you should expect the next rating to be made available sometime around April 28, 2023.
分析師在進行了廣泛的研究後得出了股票評級,其中包括查看公開的財務報表,與Aytu BioPharma的高管和客户交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。Aytu BioPharma的上一次評級是在2022年4月28日提交的,所以你應該預計下一次評級將在2023年4月28日左右的某個時候提供。
While ratings are subjective and will change, the latest Aytu BioPharma (AYTU) rating was a maintained with a price target of $24.00 to $11.00. The current price Aytu BioPharma (AYTU) is trading at is $0.62, which is out of the analyst's predicted range.
雖然評級是主觀的,並將發生變化,但最新的Aytu BioPharma(AYTU)評級維持不變,目標價在24.00美元至11.00美元之間。Aytu BioPharma目前的股價為0.62美元,超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧